[1] |
高福锋, 张师前. 子宫颈癌的预防与规范化诊疗[J]. 中国临床医生杂志, 2023, 51(3): 258-263. DOI: 10.3969/j.issn.2095-8552.2023.03.002.
|
[2] |
赵新月, 胡莉钧. 局部晚期宫颈癌预后影响因素的研究进展[J]. 癌症进展, 2023, 21(15): 1635-1638. DOI: 10.11877/j.issn.1672-1535.2023.21.15.04.
|
[3] |
汤怀鹏, 冉启玉, 周佳玲, 等. 根治性子宫切除术前宫颈锥切对早期宫颈癌患者预后影响研究进展[J]. 现代妇产科进展, 2022, 31(12): 956-958. DOI: 10.13283/j.cnki.xdfckjz.2022.12.013.
|
[4] |
于婷, 李芝伟, 刘莎, 等. 早期宫颈癌锥切标本病理因素预测淋巴结转移风险的研究进展[J]. 现代肿瘤医学, 2023, 31(11): 2161-2163. DOI: 10.3969/j.issn.1672-4992.2023.11.034.
|
[5] |
Geesala R, Issuree PD, Maretzky T. Novel functions of inactive rhomboid proteins in immunity and disease[J]. J Leukoc Biol, 2019, 106(4): 823-835. DOI: 10.1002/JLB.3VMR0219-069R.
|
[6] |
Lee MY, Nam KH, Choi KC. iRhoms; its functions and essential roles[J]. Biomol Ther (Seoul), 2016, 24(2): 109-114. DOI: 10.4062/biomolther.2015.149.
|
[7] |
Sieber B, Lu F, Stribbling SM, et al. iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells[J]. J Cell Sci, 2022, 135(17): jcs259949. DOI: 10.1242/jcs.259949.
|
[8] |
Oikonomidi I, Burbridge E, Cavadas M, et al. iTAP, a novel iRhom interactor, controls TNF secretion by policing the stability of iRhom/TACE[J]. Elife, 2018, 7: e35032. DOI: 10.7554/eLife.35032.
|
[9] |
中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 474-489. DOI: 10.19401/j.cnki.1007-3639.2021.06.06.
|
[10] |
中国医师协会微无创医学专业委员会妇科肿瘤学组专业委员会, 中国妇幼保健协会生育力保存专业委员会. 早期子宫颈癌保留生育功能手术的中国专家共识[J]. 中国微创外科杂志, 2021, 21(8): 673-679. DOI: 10.3969/j.issn.1009-6604.2021.08.001.
|
[11] |
李静, 索红燕, 孔为民. 《国际妇产科联盟(FIGO)2018癌症报告: 宫颈癌新分期及诊治指南》解读[J]. 中国临床医生杂志, 2019, 47(6): 646-649. DOI: 10.3969/j.issn.2095-8552.2019.06.008.
|
[12] |
Zhao X, Wang B, Zhuang Y, et al. Single high-dose irradiation-induced iRhom2 upregulation promotes macrophage antitumor activity through cGAS/STING signaling[J]. Int J Radiat Oncol Biol Phys, 2023, 116(5): 1150-1162. DOI: 10.1016/j.ijrobp.2023.02.013.
|
[13] |
Blaydon DC, Etheridge SL, Risk JM, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome[J]. Am J Hum Genet, 2012, 90(2): 340-346. DOI: 10.1016/j.ajhg.2011.12.008.
pmid: 22265016
|
[14] |
Agwae ME, Shaw RJ, Triantafyllou A, et al. iRhom2 in the pathogenesis of oral squamous cell carcinoma[J]. Mol Biol Rep, 2020, 47(5): 3987-3992. DOI: 10.1007/s11033-020-05381-y.
pmid: 32236893
|
[15] |
Adrain C, Zettl M, Christova Y, et al. Tumor necrosis factor signa-ling requires iRhom2 to promote trafficking and activation of TACE[J]. Science, 2012, 335(6065): 225-228. DOI: 10.1126/science.1214400.
pmid: 22246777
|
[16] |
Luo Z, Huang Y, Batra N, et al. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy[J]. Nat Commun, 2024, 15(1): 255. DOI: 10.1038/s41467-023-44572-6.
pmid: 38177179
|
[17] |
Al-Salihi MA, Lang PA. iRhom2: an emerging adaptor regulating immunity and disease[J]. Int J Mol Sci, 2020, 21(18): 6570. DOI: 10.3390/ijms21186570.
|
[18] |
Badenes M, Adrain C. iRhom2 and TNF: partners or enemies?[J]. Sci Signal, 2019, 12(605): eaaz0444. DOI: 10.1126/scisignal.aaz0444.
|
[19] |
Giese AA, Babendreyer A, Krappen P, et al. Inflammatory activation of surface molecule shedding by upregulation of the pseudoprotease iRhom2 in colon epithelial cells[J]. Sci Rep, 2021, 11(1): 24230. DOI: 10.1038/s41598-021-03522-2.
pmid: 34930929
|
[20] |
Zhao Z, Kesti T, Uğurlu H, et al. Tyrosine phosphorylation directs TACE into extracellular vesicles via unconventional secretion[J]. Traffic, 2019, 20(3): 202-212. DOI: 10.1111/tra.12630.
pmid: 30569492
|
[21] |
Xu Q, Chen C, Liu B, et al. Association of iRhom1 and iRhom2 expression with prognosis in patients with cervical cancer and possible signaling pathways[J]. Oncol Rep, 2020, 43(1): 41-54. DOI: 10.3892/or.2019.7389.
pmid: 31661139
|